keyword
MENU ▼
Read by QxMD icon Read
search

Thrombocytosis and prematurity

keyword
https://www.readbyqxmd.com/read/27704652/epidemiology-clinical-characteristics-laboratory-findings-and-severity-of-respiratory-syncytial-virus-acute-lower-respiratory-infection-in-malaysian-children-2008-2013
#1
Khuen F Ng, Kah K Tan, Zhi H Sam, Grace Ss Ting, Wan Y Gan
AIM: The aim of this study is to describe epidemiology, clinical features, laboratory data and severity of respiratory syncytial virus (RSV) acute lower respiratory infection (ALRI) in Malaysian children and to determine risk factors associated with prolonged hospital stay, paediatric intensive care unit (PICU) admission and mortality. METHODS: Retrospective data on demographics, clinical presentation, outcomes and laboratory findings of 450 children admitted into Tuanku Jaafar Hospital in Seremban, Malaysia from 2008 to 2013 with documented diagnosis of RSV ALRI were collected and analysed...
October 5, 2016: Journal of Paediatrics and Child Health
https://www.readbyqxmd.com/read/26267420/the-effect-of-clozapine-on-hematological-indices-a-1-year-follow-up-study
#2
Jimmy Lee, Hiroyoshi Takeuchi, Gagan Fervaha, Valerie Powell, Amaal Bhaloo, Robert Bies, Gary Remington
Clozapine is the antipsychotic of choice for treatment-resistant schizophrenia and is linked to a need for mandatory hematological monitoring. Besides agranulocytosis, other hematological aberrations have resulted in premature termination in some cases. Considering clozapine's role in immunomodulation, we proceeded to investigate the impact of clozapine on the following 3 main hematological cell lines: red blood cells, platelets, white blood cells (WBCs), and its differential counts. Data were extracted from patients initiated on clozapine between January 2009 and December 2010 at a single hospital...
October 2015: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/21173946/mixed-hepatoblastoma-in-child-case-report
#3
REVIEW
Daniela Iacob, Alexandru Serban, Otilia Fufezan, Radu Badea, Cornel Iancu, Călin Mitre, Stefania Neamţu
Hepatoblastoma represents the child's most frequent malignant hepatic tumor. We present the case of a one-year old prematurely born patient with an abdominal mass. Ultrasound and CT scan demonstrated a solid hepatic tumor. Serum alpha fetoprotein level was increased. He presented thrombocytosis and a left lobe hepatectomy was performed. Pathological examination revealed complete excision of a mixed hepatoblastoma. Hepatic tumor at a child under 3 years old correlated with elevated serum alpha fetoprotein and thrombocytosis are almost patognomonic for hepatoblastoma...
June 2010: Medical Ultrasonography
https://www.readbyqxmd.com/read/20966892/preclinical-and-clinical-activity-of-atp-mimetic-jak2-inhibitors
#4
REVIEW
Martha Wadleigh, Ayalew Tefferi
The discovery of a common Janus kinase 2 (JAK2) point mutation, JAK2V617F, in myeloproliferative neoplasms has generated enormous interest in the development and therapeutic use of small molecule JAK2 inhibitor-targeted therapy in these diseases. A handful of compounds are currently in clinical development in primary myelofibrosis or post-polycythemia vera (PV)/essential thrombocythemia (ET) myelofibrosis. To date, clinical benefit has been demonstrated in terms of reduction of splenomegaly, improvement in constitutional symptoms, and control of leukocytosis...
August 2010: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/20689518/comparison-between-one-and-three-doses-a-week-of-recombinant-erythropoietin-in-very-low-birth-weight-infants
#5
RANDOMIZED CONTROLLED TRIAL
M Á Vázquez López, M Á Llamas, R Galera, A R Sanchez, F Lendinez, M Gonzalez-Ripoll, J Díez, A Bonillo
OBJECTIVE: To compare transfusion requirements and erythropoietic response in preterms between schedules of rEPO administration once or three times per week, using the same weekly dose. STUDY DESIGN: Prospective, randomized trial including infants weighing <1500 g at birth and/or were 32 weeks' gestation: Group 1 (60 infants) received subcutaneous rEPO at 250 units kg(-1) per dose, three times weekly for 6 weeks; Group 2 (59 infants), at 750 units kg(-1) per dose, once weekly for 6 weeks...
February 2011: Journal of Perinatology: Official Journal of the California Perinatal Association
https://www.readbyqxmd.com/read/20632251/thrombotic-complications-of-erythropoiesis-stimulating-agents
#6
REVIEW
Giuseppe Lippi, Massimo Franchini, Emmanuel J Favaloro
The synthesis of erythropoiesis-stimulating agents (ESAs), especially recombinant human erythropoietin, has provided a new therapeutic option for the treatment of patients with various forms of anemia, including that of chronic renal disease, malignancy, hematologic disorders, prematurity, and acquired immune deficiency syndrome. These agents are effective in improving the hematologic response and reducing the need for red blood cells transfusion, and they also appear to have a positive effect on some health-related quality-of-life indicators...
July 2010: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/20092024/pathology-in-children-of-hiv-women
#7
Ana Pilar Nso Roca, C García-Bermejo García-Bermejo, B Larru, Madero R, M A Muñoz Fernández, M I de José
OBJECTIVE: To assess the frequency of perinatal pathology in children exposed to antiretrovirals in perinatal period. DESIGN: Retrospective observational cohort study. METHODS: Retrospective observational cohort study. Data collected among uninfected children born to HIV-infected women followed up from 1994 to 2006 in a tertiary Hospital. 220 uninfected children were studied. Factors studied included maternal, obstetrical and pediatric variables...
November 2009: Indian Journal of Pediatrics
https://www.readbyqxmd.com/read/19798040/thrombocytosis-in-neonates-and-young-infants-a-report-of-25-patients-with-platelet-counts-of-or-1000000-microl-1
#8
S E Wiedmeier, E Henry, J Burnett, T Anderson, R D Christensen
OBJECTIVE: Thrombocytosis has been reported in neonates and young infants, but little is known of its prevalence, timing of onset, associated conditions, sequelae and outcomes. To better understand this condition, we used the data repositories of a multi-hospital health-care system to identify all individuals <or=140 days old (20 weeks) who, during the past 6 years, had a platelet count of >or=1000000 microl(-1). STUDY DESIGN: We identified all infants with extreme thrombocytosis (using the Sutor definition of a platelet count of >or=1000000 microl(-1)) during the period of January 2003 through December 2008 in any Intermountain Healthcare facility...
March 2010: Journal of Perinatology: Official Journal of the California Perinatal Association
https://www.readbyqxmd.com/read/19711442/prolonged-acquired-neutropenia-in-children
#9
Jiunn-Ming Sheen, Ho-Chang Kuo, Hong-Ren Yu, Eng-Yen Huang, Chih-Chiang Wu, Kuender D Yang
BACKGROUND: Acquired neutropenia is not uncommon in childhood. This study investigated the risk factors associated with developing prolonged acquired neutropenia. PROCEDURE: We reviewed 66,062 hospital admission medical records from the 5-year period January 1, 2002 to December 31, 2006 to identify neutropenic patients, with and without follow-up of their neutropenic course until December 31, 2007. After excluding patients with malignancy, collagen disease, bone marrow failure, prematurity, hereditary disease, congenital neutropenia, immunodeficiency, or status post-liver transplantation, 735 admissions with acquired neutropenia were included in our study...
December 15, 2009: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/18818663/platelet-reference-ranges-for-neonates-defined-using-data-from-over-47-000-patients-in-a-multihospital-healthcare-system
#10
S E Wiedmeier, E Henry, M C Sola-Visner, R D Christensen
OBJECTIVE: Identifying a platelet count as abnormal (thrombocytopenia or thrombocytosis) can facilitate recognizing various disease states. However, the published reference ranges for platelet counts in neonates may be imprecise, as they were generated from relatively small sample sizes and compiled before modern platelet enumeration methods. STUDY DESIGN: We derived new neonatal reference ranges for platelet counts and mean platelet volume (MPV) measurements using electronic data accumulated during a recent 6-year period from a multihospital healthcare system...
February 2009: Journal of Perinatology: Official Journal of the California Perinatal Association
https://www.readbyqxmd.com/read/18802685/regional-cooling-of-the-extracorporeal-blood-circuit-a-novel-anticoagulation-approach-for-renal-replacement-therapy
#11
Ales Krouzecky, Jiri Chvojka, Roman Sykora, Jaroslav Radej, Thomas Karvunidis, Ivan Novak, Jiri Ruzicka, Zuzana Petrankova, Jiri Benes, Lukas Bolek, Martin Matejovic
OBJECTIVE: To test the hypothesis that cooling of blood in the extracorporeal circuit of continuous veno-venous hemofiltration (CVVH) enables to realize the procedure without the need of anticoagulation. DESIGN: Experimental animal study. METHODS: We developed the device for selective cooling of extracorporeal circuit (20 degrees C) allowing blood rewarming (38 degrees C) just before returning into the body. Twelve anesthetized and ventilated pigs were randomized to receive either 6 h of CVVH with application of this device (COOL; n = 6) or without it (CONTR; n = 6)...
February 2009: Intensive Care Medicine
https://www.readbyqxmd.com/read/16764090/anagrelide-new-drug-essential-thrombocythaemia-further-evaluation-needed-for-this-last-resort-treatment
#12
COMPARATIVE STUDY
(no author information available yet)
(1) For patients aged over 60 years who have essential thrombocythaemia, and are considered to be at increased risk of thromboembolism, the standard cytotoxic agent is hydroxycarbamide (hydroxyurea), which reduces the risk of thrombocytosis but adversely affects other blood cell lines. It may also increase the risk of progression to cancer. (2) Anagrelide, initially studied as an antiplatelet drug, was approved in Europe for the treatment of essential thrombocythaemia in high-risk patients when other treatments fail or are poorly tolerated...
June 2006: Prescrire International
https://www.readbyqxmd.com/read/15647951/thrombocytosis-in-preterm-infants-a-possible-involvement-of-thrombopoietin-receptor-gene-expression
#13
Hideki Nakayama, Kenji Ihara, Shunji Hikino, Junko Yamamoto, Taro Nagatomo, Megumi Takemoto, Toshiro Hara
Transient thrombocytosis is commonly observed in preterm infants after birth, but its physiological mechanism is still unknown. To understand the mechanism of the transient thrombocytosis in preterm infants we firstly evaluated a correlation between platelet counts and thrombopoietin (TPO) levels in preterm infants and next c-mpl mRNA levels on platelets in healthy preterm infants longitudinally during a half-year of life. The mean platelet counts in 45 very low birth weight infants (mean gestational age 27...
April 2005: Journal of Molecular Medicine: Official Organ of the "Gesellschaft Deutscher Naturforscher und Ärzte"
https://www.readbyqxmd.com/read/15578031/patterns-of-thrombocytosis-and-thrombocytopenia-in-hospitalized-neonates
#14
Ronald J McPherson, Sandra Juul
OBJECTIVE: We sought to identify changes in platelet (PLT) counts over time, and to evaluate the patterns of thrombocytopenia and thrombocytosis in hospitalized infants 23.8 weeks to term gestation. STUDY DESIGN: Neonates were divided into four gestational age groups and their PLT counts were retrospectively compared for prevalence of thrombocytopenia, thrombocytosis, and associated conditions. RESULTS: Postconceptional age, postnatal age, and sepsis (among other factors) affected PLT counts...
March 2005: Journal of Perinatology: Official Journal of the California Perinatal Association
https://www.readbyqxmd.com/read/15034233/age-dependent-changes-in-the-incidence-and-etiology-of-childhood-thrombocytosis
#15
Kousaku Matsubara, Takashi Fukaya, Hiroyuki Nigami, Hidekazu Harigaya, Takuya Hirata, Hideo Nozaki, Kunizo Baba
To determine the incidence and etiology of childhood thrombocytosis, over 15,000 platelet counts in 7,539 patients performed at a single regional hospital were reviewed. When thrombocytosis was defined as > or =500 x 10(9)/l of platelet counts, the condition could be diagnosed in 6.0% (456 cases) of the patients. All patients were classified as having secondary thrombocytosis. The incidence of thrombocytosis dramatically changed throughout child development; it was 12.5% in neonates, peaked to 35.8% in 1-month-old infants and then returned to 12...
2004: Acta Haematologica
https://www.readbyqxmd.com/read/11843834/early-elevation-of-serum-thrombopoietin-levels-and-subsequent-thrombocytosis-in-healthy-preterm-infants
#16
K Matsubara, K Baba, H Nigami, H Harigaya, A Ishiguro, T Kato, H Miyazaki
To verify pathophysiological mechanisms underlying thrombocytosis in low-birth-weight (LBW) preterm babies, we evaluated kinetic changes in platelet counts and thrombopoietic cytokines including thrombopoietin (TPO), interleukin 6 (IL-6) and IL-11 in 24 uncomplicated preterm infants. Platelet counts in cord blood (CB) (265 +/- 64 x 10(9)/l) were similar to adult levels, increased by d 14 (473 +/- 140 x 10(9)/l), and then remained fairly constant. Thrombocytosis (> 500 x 10(9)/l) was observed in 9/24 (38%) subjects...
December 2001: British Journal of Haematology
https://www.readbyqxmd.com/read/11237230/meropenem-in-neonatal-severe-infections-due-to-multiresistant-gram-negative-bacteria
#17
N Köksal, M Hacimustafaoğlu, S Bağci, S Celebi
Recently, new broad spectrum carbapenem has been investigated on a world-wide scale for the treatment of moderate to severe infections. In the neonatal intensive care units the extensive use of third generation cephalosporins for therapy of neonatal sepsis may lead to rapid emergence of multiresistant gram-negative organisms. We report the use of meropenem in 35 infants with severe infections due to Acinetobacter baumanii and Klebsiella pneumoniae. All gram negative bacteria were resistant to ampicillin, amoxicillin, ticarcilin, cefazoline, cefotaxime, ceftazidime, ceftriaxone and aminoglycosides...
January 2001: Indian Journal of Pediatrics
https://www.readbyqxmd.com/read/10910539/thrombocytosis-in-children-at-one-medical-center-of-southern-taiwan
#18
H L Chen, S S Chiou, J M Sheen, R C Jang, C C Lu, T T Chang
Thrombocytosis in children is common, but usually without symptoms. The causes of thrombocytosis in children are considered to be mostly due to infection, trauma, surgery, blood disease, prematurity, renal disease and chronic inflammation. To evaluate the incidence and etiology of thrombocytosis of the hospitalized patients, patients who were admitted to the Pediatric Department of Kaohsiung Medical College Hospital (KMCH) from October 1996 to November 1997 were studied. There were 2910 cases studied and 220 cases (127 male and 93 female) had thrombocytosis (> or = 500 x 10(9)/L) with a rate of 7...
September 1999: Acta Paediatrica Taiwanica, Taiwan Er Ke Yi Xue Hui za Zhi
https://www.readbyqxmd.com/read/10828006/translational-pathophysiology-a-novel-molecular-mechanism-of-human-disease
#19
REVIEW
M Cazzola, R C Skoda
In higher eukaryotes, the expression of about 1 gene in 10 is strongly regulated at the level of messenger RNA (mRNA) translation into protein. Negative regulatory effects are often mediated by the 5'-untranslated region (5'-UTR) and rely on the fact that the 40S ribosomal subunit first binds to the cap structure at the 5'-end of mRNA and then scans for the first AUG codon. Self-complementary sequences can form stable stem-loop structures that interfere with the assembly of the preinitiation complex and/or ribosomal scanning...
June 1, 2000: Blood
https://www.readbyqxmd.com/read/10790464/effect-of-early-versus-late-administration-of-human-recombinant-erythropoietin-on-transfusion-requirements-in-premature-infants-results-of-a-randomized-placebo-controlled-multicenter-trial
#20
RANDOMIZED CONTROLLED TRIAL
H Donato, N Vain, P Rendo, N Vivas, L Prudent, M Larguía, J Digregorio, C Vecchiarelli, R Valverde, C García, P Subotovsky, C Solana, A Gorenstein
OBJECTIVE: The administration of recombinant human erythropoietin (rHuEPO), started after the first 2 weeks of life, reduces the transfusion requirement in premature infants. However, its use throughout the first 2 weeks of life, when anemia results predominantly from phlebotomy losses, remains controversial. We investigated whether early use of rHuEPO would reduce the total transfusion requirement and/or the number of transfusions throughout the first 2 weeks of life. METHODS: We randomized 114 infants with birth weight (BW) <1250 g to receive rHuEPO (1250 units/kg/week; IV; early group: n = 57) or placebo (late group: n = 57) from day 2 to day 14 of life; subsequently, all the patients received rHuEPO (750 units/kg/week, subcutaneously) for 6 additional weeks...
May 2000: Pediatrics
keyword
keyword
62391
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"